The UK’s life sciences sector is at a crucial crossroads but just a few miles south of Manchester on the edge of the Peak District is a success story
Now one of the UK’s largest drug discovery research sites its expanded integrated drug discovery facilities at its Chapel-en-le-Frith site.
The expansion brings chemistry, ADMET and screening biology capabilities together under one roof with 130 scientists now on the site of Concept Life Sciences
The Company’s mission is to accelerate the development of life-changing therapies, enhancing its ability to provide streamlined integrated drug discovery services that unlock progress in early-stage innovation and bring much needed drugs quicker to the market
Whilst the average waiting time in the industry can be up to sixty two months, Concept Life Sciences can do the same process in twenty eight months
Concept Life Sciences has around 230 employees, with over 70% holding PhDs.
Operating from its Peak District Headquarters it has additional specialist operations in Edinburgh, Dundee, and Sandwich.
Local MP Jon Pearce,present at the opening ceremony described the work done at the Town’s largest employer as simply incredible adding:
It is fantastic to see Concept Life Sciences investing in Chapel-en-le-Frith and creating one of the UK’s leading drug discovery research sites here in High Peak. This expansion not only brings high-skilled, high-value jobs to our community, but also puts our region at the forefront of groundbreaking work to develop life-changing therapies. It shows the enormous potential for growth in life sciences both here in High Peak and across the UK
The expanded state-of-the-art facilities which has seen over £2.5 million In investments includes custom-fit drug discovery solutions across a broad range of modalities and therapy areas, are also expected to provide high-value life-sciences job opportunities in the Manchester and Sheffield region.
Jonathan Critchley, Chief Financial Officer at Concept Life Sciences, commented: “This expansion of our facilities further strengthens our ability to turn breakthrough science into viable, fundable and clinically impactful therapies through our integrated drug discovery capabilities.
